Assembly Biosciences, Inc. (NASDAQ:ASMB) Stock Has Average Price Target of $47.50 According to Analysts

Key Points

• Analysts hold a Moderate Buy consensus on Assembly Biosciences, with four buy ratings, one strong-buy, and one sell recommendation. The average 12-month price target is $47.50, well above the stock’s $22.54 opening price.
• Assembly Biosciences reported a quarterly loss of $0.20 per share, beating the $0.72 consensus loss estimate, while revenue of $13.37 million exceeded expectations of $8.60 million.
• Institutional ownership stands at 19.92%, with several investment firms recently increasing their positions; however, the stock remains near its 52-week low of $21.80 and below its 50-day moving average of $29.09.

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $47.50.

A number of research analysts have recently commented on the stock. Mizuho set a $53.00 price objective on shares of Assembly Biosciences in a research note on Tuesday, September 1st. HC Wainwright reissued a "buy" rating and issued a $50.00 target price on shares of Assembly Biosciences in a research report on Tuesday, August 18th. Weiss Ratings restated a "sell (d-)" rating on shares of Assembly Biosciences in a report on Friday, July 17th. UBS Group initiated coverage on shares of Assembly Biosciences in a research report on Tuesday, September 1st. They set a "buy" rating and a $52.00 price target for the company. Finally, Zacks Research raised shares of Assembly Biosciences from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 20th.

Institutional Trading of Assembly Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in ASMB. Arrowstreet Capital Limited Partnership boosted its holdings in Assembly Biosciences by 4.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 39,446 shares of the biopharmaceutical company's stock valued at $1,095,000 after acquiring an additional 1,634 shares during the last quarter. Seven Fleet Capital Management LP acquired a new stake in Assembly Biosciences during the fourth quarter worth about $147,000. Bank of America Corp DE raised its holdings in shares of Assembly Biosciences by 113.3% in the 1st quarter. Bank of America Corp DE now owns 10,902 shares of the biopharmaceutical company's stock worth $303,000 after purchasing an additional 5,792 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Assembly Biosciences by 69.4% in the 1st quarter. Renaissance Technologies LLC now owns 15,651 shares of the biopharmaceutical company's stock worth $434,000 after purchasing an additional 6,411 shares during the period. Finally, Engineers Gate Manager LP raised its holdings in shares of Assembly Biosciences by 88.5% in the 2nd quarter. Engineers Gate Manager LP now owns 17,766 shares of the biopharmaceutical company's stock worth $488,000 after purchasing an additional 8,343 shares during the period. 19.92% of the stock is currently owned by institutional investors and hedge funds.

Assembly Biosciences Stock Down 1.9%

ASMB stock opened at $22.54 on Friday. The stock has a market capitalization of $458.91 million, a price-to-earnings ratio of 22.10 and a beta of 1.15. Assembly Biosciences has a 52-week low of $21.80 and a 52-week high of $39.71. The stock's fifty day simple moving average is $29.09 and its 200-day simple moving average is $27.91.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last released its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.52. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%.The firm had revenue of $13.37 million during the quarter, compared to analyst estimates of $8.60 million. As a group, analysts anticipate that Assembly Biosciences will post 2.28 earnings per share for the current fiscal year.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a clinical-stage biotechnology company focused on developing oral therapeutics for serious viral diseases. The company's research programs target viral replication and other essential processes, with an emphasis on treatments that may improve outcomes for patients with limited therapeutic options.

Assembly's pipeline has included investigational therapies for chronic hepatitis B virus (HBV) infection, including core or capsid assembly modulators designed to interfere with the virus's life cycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.